Abstract PO4-04-12: A Phase 1b/2 Study of Palazestrant (OP-1250) in Combination with Ribociclib or Alpelisib in Patients with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced And/or Metastatic Breast Cancer
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined